ABSTRACT
INTRODUCTION
The prime-boost strategies are considered as a promising approach for elicitation of humoral and cellular immunity to a variety of pathogens and have demonstrated efficacy in humans (Woodland, 2004) . Acquired immunodeficiency syndrome (AIDS) was first reported in 1981 (CDC, 1981). Two years later, the responsible retrovirus was isolated, at the same time, at National Cancer Institute in Bethesda, Maryland, USA (Galloet al., 1983) and the Pasteur Institute in France (Barré-Sinoussiet al., 1983).This virus was later named as Human Immunodeficiency Virus (HIV) by the International Committee on Taxonomy of Viruses in 1986 (Coffin et al., 1986).The mature HIV-1 particle is roughly round with diameter of about 100 nm. HIV-1 is enveloped with a thick lipid bilayer membrane derived from the membrane of host cells during budding process. On each HIV virion, there are only about 8-14 envelope glycoprotein spikes (Zanetti et al., 2006 and Zhu et al., 2006) .The HIV-1 envelope glycoprotein composed of the receptor binding domain gp120 and the fusion protein subunit gp41 which catalyzes virus entry and is a major target for therapeutic intervention and for neutralizing antibodies (Buzon et al., 2010).Until recently, mapping and structural definition of the HIV-1 has allowed the identification of five sites of vulnerability to neutralizing antibodies on the HIV-1 trimeric complex. These five sites are (1) CD4 binding site (CD4bs), (2) N-glycan V1/V2 loop, (3) Nglycan V3 loop, (4) gp120/gp41 interface, (5) 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-dioleoyl-snglycero-3-phospho-(1'-rac-glycerol) (DOPG) and 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC) (Avanti Polar Lipids, Alabaster, AL, USA) at molar percentages 0.5: 0.2: 40: 20: 40. Then, drying them under a nitrogen stream to obtain a thin lipid film and placing them under vacuum at room temperature for overnight. Afterwards, the lipid film was hydrated with PBS pH 7.4 and CD4 + T-helper peptide LACK(Leishmania homolog of receptors for activated C-kinase), even hydration and initial liposome sizing was performed by vortexing 6 times for 30 seconds each at 5-minutes intervals, followed by 6 rounds of flash freezing in liquid nitrogen for 1 minute and thawing at 37°C water bath for 5 minutes, and finally extrusion 21 times through a 200-nm-pore-size polycarbonate membrane (Whatman Inc., USA).
Immunization
Immunizations were performed by intradermal injection with 50µL of HIV1 gp41 (662-683) loaded liposomes being delivered in each hind flank. BALB/c Mice received the first immunization(prime) on day zero and the second immunization(booster dose) on day 30. Sera were collected on day zero (preimmunization negative control), 30 days postpriming, and 30 days post-boosting (Figure 1 ). Mice were sacrificed on day 30 post-boost and bone marrow cells were harvested for ELISPOT. 
ELISA Quantification of antigen-specific antibody response
Blood (~50µl) were collected from tail veins of gently-warmed mouse (under a heat lamp) into a polypropylene microcentifuge tube. Blood was maintained at room temperature and was allowed to coagulate. Serum was then separated by centrifugation for 5 minutes in microcentrifuge at high speed (12000 rpm). Serum was collected and stored at -20 °C until assayed.
Immuno 2HB Plates with 96 wells (Thermo Fisher Scientific) were coated overnight with 2 µg/ml streptavidin diluted in PBS (50 µl/well) at 4°C for attachment of biotinylated liposomes. The wells were washed three times with blank buffer(0.1% BSA-PBS)for removing of free streptavidin and blocked for 3 hr with 200µl 1% BSA-PBS to fillover the left empty sides. Blocking solution was discarded and wells were incubated with 0.2% biotinylated polyethylene glycol (PEG) 2000-containing HIV-1 gp41 (662-683) or LACK liposomes (1:50 peptid: lipid ratio & 4:1 DOPC:DOPG ratio) at 32 µg/ml in 100µl 1% BSA-PBS for 2 hr with shaking at room temperature and then for another 2 hr at 4°C. Wells were washed again, incubated overnight at 4°C with serial dilutions of sera (1:100-1:500000) in blank buffer. For positive and negative controls, respectively, anti-MPER recombinant monoclonal antibody 2F5 and blank buffer were used(Doniuset al., 2016).
The next day, serum samples were removed, the plate was washed and goat antimouse-horseradish peroxidase (HRP) secondary antibody at a 1:2000 dilution was applied for 1 hr at 4°C. Plate was washed two times with 0.1% BSA PBS and two times with PBS. Bound antibody was detected by incubation with o-phenylenediamine (OPD) solution in citrate buffer, pH 4.5, for 10 minutes. The OPD reaction was stopped with 2.25M H 2 SO 4 , and the absorbance was read at 490 nm on a Victor X4 plate reader (PerkinElmer, USA).
ELISPOT quantification of peptide-specific antibody-secreting cells
Quantification of HIV1 gp41(662-683)-specific antibody-secreting cells (ASCs) from bone marrow (BM) was performed using ELISPOT assay (Doniuset al., 2016). Mouse BM was collected from the combined femurs and tibias by removing the ends of the bones and flushing the cells out with PBS. BM red blood cells were further lysed by 1 ml of Ammonium-Chloride-Potassium (ACK) lysing buffer (Thermo Fisher Scientific) and the BM cells were resuspended in a buffer (0.5% BSA, 2mM EDTA in PBS).
Briefly, 96-well 0.45-µm, hydrophobic, high protein-binding Immobilon-P polyvinylidenedifluoride (PVDF) membrane plates (EMD Millipore, USA) was pretreated with 30 µl 35% ethanol and washed eight times with sterile water. Plates were coated with 100 µl per well of 100 µg/ml HIV-1gp41 (662-683) liposome diluted in PBS (1:50 peptide: lipid ratio; 4:1 DOPC: DOPG ratio) and incubated overnight at 4°C. Plates were washed six times with 0.1% BSA-PBS and blocked with 200 µl/well 1% BSA-PBS for at least 4 hr. Plates then washed once with RPMI 1640 medium supplemented with 10% FBS, glutamine, 2-mercaptoethanol, and penicillin-streptomycin, and then blocked for 1 hr at 37°C with the same medium. BM cells were strained by 70 µm-size strainer, quantified using a hemacytometer, resuspended to 1×10 7 cells/ml, restrained to 70 µm again and added to wells, in triplicate. Broadly neutralizing antibody 2F5-expressing cells were plated as positive controls. Plates incubated overnight at 37°C and 5% CO 2 in a humidified chamber. The next day, wells were washed six times with 0.1% BSA-PBS and blocked for 1.5 hr with 1% BSA-PBS and then 0.6 µg/ml of alkaline phosphatase-conjugated goat anti-mouse secondary antibodies anti-IgG diluted in 1% BSA-PBS added for 1.5 hr at room temperature. Anti-MPER broadly neutralizing antibody 2F5-secreting control cells were visualized using goat anti-human IgG-alkaline phosphatase. Plates were washed The numbers 1-5 are referring to immunized mouse code.
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Figure 2: Anti-HIV-1 gp41 (662-683) specific antibody titer.
eight times with 0.1% BSA-PBS and spots were developed by the addition of 100 µl/well 5-bromo-4-chloro-3-indolyl phosphate/nitro blue tetrazolium (BCIP/NBT) solution for 5 minutes. Plates were washed extensively with distilled water and dried overnight at room temperature. Spots were quantified using a CTL ImmunoSpot ELISPOT plate reader and ImmunoSpot 3 software (CTL, Shaker Heights, USA).
RESULTS
Ultimately, the quality of the humoral immune response is defined by the quantity and quality of antibodies produced in response to antigen. Using ELISA to assess how boosting modulated the final outcome of the circulating antibody in the sera. HIV-1 gp41 (662-683) loaded liposomes was used for testing how does self-boosting strategy enhance generation of cellular and humoral response to HIV-1 gp41 (662-683) segment. Sera were collected on days zero (pre-immunization control), day 30 post-prime and day 30 post-boost. Then, peptide-(HIV-1 gp41 "662-683" or LACK) arrayed liposomes used for detecting HIV-1 gp41 (662-683) or LACK specific antibodies by ELISA. Blank buffer was used as a negative control.
Peptide-specific antibody response elicited after primary and secondary immunization ELISA optical density at 490nm reading of the primary immune response at day 30 post immunization to HIV-1 gp41 (662-683) and LACK revealed only a trace antibody response against HIV-1 gp41 (662-683) and LACK, but response was elevated by boosting on day 30. The secondary immune response at day 30 post-boost to HIV-1 gp41 (662-683) and LACK showed increasing of anti-gp41 (662-683) (Table 1& Figure 2 ) and anti-LACK response (Table 2 and Figure 3) . HIV-1 gp41 specific antibody 2F5 and buffer blank were used as, respectively, positive and negative controls in all ELISA plates to double check the efficiency of coating peptide/liposomes. The numbers 1-5 are referring to immunized mouse code.
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Figure 3: Anti-LACK specific antibody titer.
Quantification of specific ASCs in BM after secondary immunization
The humoral response provided a global view of the total HIV-1 gp41 (662-683)-specific responses; however, a cell-specific quantification of the HIV-1 gp41 (662-683) responses was done. BALB/c mice were immunized at day 0 and day 30 with LACK loaded HIV-1 gp41 (662-683) liposomes and then sacrificed at day 30 post second immunization. The bone marrow cells were isolated and screened against HIV-1 gp41 (662-683) loaded liposomes at a peptide to lipid ratio of 1:50. All immunized mouse showed HIV-1 gp41 (662-683)-specific antigen secreting cells in bone marrow. No significant difference between quantification of HIV-1 gp41-specific antigen secreting cells generated, between immunized mice(average ~37.3 ASCs/10 6 cells) (Table 3) . Coupled with recent advances in understanding of the mechanisms underlying the generation, maintenance and recall of T-cell memory, the field is poised to make tremendous progress (Woodland, 2004) . Over the past few years, significant effort has been directed toward developing vaccines designed to promote potent humoral and cellular immunity to these and related pathogens. The induction of long-term humoral and cellular immunity, however, is complex and require elicitation of T cell help and adjuvants. Given the complexity of antigen acquisition and delivery, as well as, possible interplay between competing B cells with specificity for LACK and those for gp41, it was crucial to determine the effects primeboost strategies on humoral and cellular immunity against the targeted antigen HIV-1 gp41 (662-683) and CD4 helper peptide LACK. In general, immunization of specific antigen with an immunostimulators is an effective way to generate a strong immune response, mediating efficient activation of innate immune cells and antigen presentation to antigen presenting cells with a dose dependent effect (Seder, and Hill, 2000; Bershteynet al., 2012). The tremendous power of prime-boosting was recently further highlighted as strong enough strategy for enhancing T-memory cells aimed at prolonging protection (Arinaminpathy et al.,  2012) .
In the present study, HIV-1 gp41 (662-683) loaded liposome was used to examine how second immunization is very important for modulate antibody responses of the weakly immunogenic HIV-1 gp41 (662-683) antigen. LACK was present both encapsulated in the liposomes and freely in solution in the present study. The increased HIV-1 gp41 (662-683)-specific antibody titersby second immunization compared to single immunization may be explained by increased T cell help by more LACK presentation on the HIV-1 gp41 (662-683)-specific B cells, compensating for the differences in B cell affinity. Therefore, the magnitude of the HIV-1 gp41 (662-683)-specific cellular and serological immune responses was modulated by the surface exposure of LACK as well as the quantity of LACK peptides. 
